Compare Stocks: CVKD, TXMD, ABVC, and PLRZ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$0.89 -5.0%	$1.26	$0.82 ▼ $3.40	$24.96M	0.57	104,407 shs	97,751 shs
CVKD Cadrenal Therapeutics	$1.59 -3.0%	$2.51	$1.58 ▼ $14.64	$5.85M	1.84	41,611 shs	58,973 shs
PLRZ Polyrizon	$10.49 -6.3%	$12.43	$2.88 ▼ $18.20	$23.32M	-1.5	81,042 shs	100,878 shs
TXMD TherapeuticsMD	$2.06 +1.5%	$2.06	$0.99 ▼ $2.95	$23.50M	0.61	19,549 shs	25,510 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-4.97%	-7.24%	-27.65%	-21.94%	-71.20%
CVKD Cadrenal Therapeutics	-3.05%	-14.52%	-26.73%	-69.36%	-87.61%
PLRZ Polyrizon	-6.26%	-2.42%	-22.24%	-31.26%	+60.40%
TXMD TherapeuticsMD	+1.48%	-0.96%	+0.98%	-2.83%	+85.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVC ABVC BioPharma	$0.89 -5.0%	$1.26	$0.82 ▼ $3.40	$24.96M	0.57	104,407 shs	97,751 shs
CVKD Cadrenal Therapeutics	$1.59 -3.0%	$2.51	$1.58 ▼ $14.64	$5.85M	1.84	41,611 shs	58,973 shs
PLRZ Polyrizon	$10.49 -6.3%	$12.43	$2.88 ▼ $18.20	$23.32M	-1.5	81,042 shs	100,878 shs
TXMD TherapeuticsMD	$2.06 +1.5%	$2.06	$0.99 ▼ $2.95	$23.50M	0.61	19,549 shs	25,510 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVC ABVC BioPharma	-4.97%	-7.24%	-27.65%	-21.94%	-71.20%
CVKD Cadrenal Therapeutics	-3.05%	-14.52%	-26.73%	-69.36%	-87.61%
PLRZ Polyrizon	-6.26%	-2.42%	-22.24%	-31.26%	+60.40%
TXMD TherapeuticsMD	+1.48%	-0.96%	+0.98%	-2.83%	+85.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVC ABVC BioPharma	1.00	Sell	N/A	N/A
CVKD Cadrenal Therapeutics	2.00	Hold	$13.00	717.61% Upside
PLRZ Polyrizon	1.00	Sell	N/A	N/A
TXMD TherapeuticsMD	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CVKD, TXMD, ABVC, and PLRZ Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/14/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D+)
7/29/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	CVKD Cadrenal Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	TXMD TherapeuticsMD	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/26/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/11/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/29/2026	ABVC ABVC BioPharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/21/2026	PLRZ Polyrizon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	$0.46 per share	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	$1.15 per share	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	$13.05 per share	N/A
TXMD TherapeuticsMD	$3.02M	7.89	$0.05 per share	43.51	$2.34 per share	0.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVC ABVC BioPharma	-$7.91M	-$0.30	N/A	N/A	N/A	N/A	-47.68%	-30.97%	N/A
CVKD Cadrenal Therapeutics	-$13.24M	-$4.90	N/A	N/A	N/A	N/A	-406.41%	-273.80%	11/9/2026 (Estimated)
PLRZ Polyrizon	-$3.34M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	-$570K	$0.02	103.00	N/A	N/A	-6.64%	-1.09%	-0.78%	N/A

Latest CVKD, TXMD, ABVC, and PLRZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CVKD Cadrenal Therapeutics	-$1.42	-$1.14	+$0.28	-$1.14	N/A	N/A
8/12/2026	Q2 2026	ABVC ABVC BioPharma	-$0.40	-$0.03	+$0.37	-$0.03	$0.11 million	N/A
8/11/2026	Q2 2026	TXMD TherapeuticsMD	-$6.1250	$0.01	+$6.1350	$0.01	$19.77 million	$0.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVC ABVC BioPharma	N/A	N/A	N/A	N/A	N/A
CVKD Cadrenal Therapeutics	N/A	N/A	N/A	N/A	N/A
PLRZ Polyrizon	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVC ABVC BioPharma	N/A	0.07	0.07
CVKD Cadrenal Therapeutics	N/A	3.73	3.73
PLRZ Polyrizon	N/A	29.03	29.03
TXMD TherapeuticsMD	N/A	3.22	3.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVC ABVC BioPharma	11.38%
CVKD Cadrenal Therapeutics	7.92%
PLRZ Polyrizon	N/A
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
ABVC ABVC BioPharma	19.00%
CVKD Cadrenal Therapeutics	14.59%
PLRZ Polyrizon	N/A
TXMD TherapeuticsMD	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVC ABVC BioPharma	30	26.65 million	21.59 million	Not Optionable
CVKD Cadrenal Therapeutics	4	3.57 million	3.05 million	Not Optionable
PLRZ Polyrizon	N/A	2.08 million	N/A	N/A
TXMD TherapeuticsMD	420	11.57 million	11.38 million	Optionable

CVKD, TXMD, ABVC, and PLRZ Headlines

Recent News About These Companies

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains

June 5, 2026 | marketwatch.com

TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives

May 12, 2026 | tipranks.com

TherapeuticsMD Announces First Quarter 2026 Financial Results

May 12, 2026 | businesswire.com

TherapeuticsMD Inc. stock outperforms competitors on strong trading day

April 6, 2026 | marketwatch.com

TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy

April 2, 2026 | theglobeandmail.com

TherapeuticsMD Explains Brief Delay In Annual Filing

April 1, 2026 | tipranks.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | finance.yahoo.com

TherapeuticsMD Announces Full Year 2025 Financial Results

March 30, 2026 | businesswire.com

TherapeuticsMD (NASDAQ:TXMD) Director Tommy Thompson Buys 8,400 Shares

December 30, 2025 | insidertrades.com

TherapeuticsMD approves key proposals at annual meeting

December 16, 2025 | msn.com

TherapeuticsMD: Q3 Earnings Snapshot

November 13, 2025 | timesunion.comT

TherapeuticsMD Reports Q3 2025 Financial Results

November 13, 2025 | msn.com

TherapeuticsMD Announces Third Quarter 2025 Financial Results

November 12, 2025 | businesswire.com

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, TXMD, ABVC, and PLRZ Company Descriptions

ABVC BioPharma NASDAQ:ABVC

$0.89 -0.05 (-4.97%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$0.89 +0.00 (+0.01%)

As of 08/20/2026 06:36 PM Eastern

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Cadrenal Therapeutics NASDAQ:CVKD

$1.59 -0.05 (-3.05%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$1.60 +0.00 (+0.31%)

As of 08/20/2026 04:54 PM Eastern

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Polyrizon NASDAQ:PLRZ

$10.49 -0.70 (-6.26%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$10.50 +0.01 (+0.10%)

As of 08/20/2026 05:47 PM Eastern

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

TherapeuticsMD NASDAQ:TXMD

$2.06 +0.03 (+1.48%)

As of 08/20/2026 04:00 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVKD, TXMD, ABVC, and PLRZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVKD, TXMD, ABVC, and PLRZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVKD, TXMD, ABVC, and PLRZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, TXMD, ABVC, and PLRZ Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Cadrenal Therapeutics NASDAQ:CVKD

Polyrizon NASDAQ:PLRZ

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVKD, TXMD, ABVC, and PLRZ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVKD, TXMD, ABVC, and PLRZ Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVKD, TXMD, ABVC, and PLRZ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD, TXMD, ABVC, and PLRZ Company Descriptions

ABVC BioPharma NASDAQ:ABVC

Cadrenal Therapeutics NASDAQ:CVKD

Polyrizon NASDAQ:PLRZ

TherapeuticsMD NASDAQ:TXMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools